Earnings Estimate | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2022) | Next Year (2023) |
---|---|---|---|---|
No. of Analysts | 2 | 2 | 25 | 25 |
Avg. Estimate | 14 | 14.17 | 55.77 | 62.29 |
Low Estimate | 13.3 | 13.94 | 47.7 | 49.1 |
High Estimate | 14.7 | 14.4 | 63.52 | 69.28 |
Year Ago EPS | N/A | N/A | N/A | 55.77 |
Revenue Estimate | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2022) | Next Year (2023) |
---|---|---|---|---|
No. of Analysts | 3 | 3 | 26 | 25 |
Avg. Estimate | 61.7B | 63.62B | 250.11B | 271.28B |
Low Estimate | 59.2B | 62.27B | 234.74B | 242.8B |
High Estimate | 64.52B | 65.38B | 268.4B | 298.66B |
Year Ago Sales | N/A | N/A | N/A | 250.11B |
Sales Growth (year/est) | N/A | N/A | N/A | 8.50% |
Earnings History | Invalid Date | Invalid Date | Invalid Date | 2021-06-30 |
---|---|---|---|---|
EPS Est. | N/A | N/A | N/A | 14.53 |
EPS Actual | N/A | N/A | N/A | 13.14 |
Difference | N/A | N/A | N/A | -1.39 |
Surprise % | N/A | N/A | N/A | -9.60% |
EPS Trend | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2022) | Next Year (2023) |
---|---|---|---|---|
Current Estimate | 14 | 14.17 | 55.77 | 62.29 |
7 Days Ago | 0 | 0 | 0 | 0 |
30 Days Ago | 0 | 0 | 0 | 0 |
60 Days Ago | 0 | 0 | 0 | 0 |
90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2022) | Next Year (2023) |
---|---|---|---|---|
Up Last 7 Days | N/A | N/A | 1 | N/A |
Up Last 30 Days | N/A | N/A | 1 | N/A |
Down Last 7 Days | N/A | N/A | N/A | N/A |
Down Last 30 Days | N/A | N/A | N/A | 1 |
Growth Estimates | AUROPHARMA.NS | Industry | Sector(s) | S&P 500 |
---|---|---|---|---|
Current Qtr. | N/A | N/A | N/A | N/A |
Next Qtr. | N/A | N/A | N/A | N/A |
Current Year | N/A | N/A | N/A | N/A |
Next Year | 11.70% | N/A | N/A | N/A |
Next 5 Years (per annum) | 11.30% | N/A | N/A | N/A |
Past 5 Years (per annum) | 8.19% | N/A | N/A | N/A |